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ABSTRACT
The 2A protein of Theiler’s murine encephalomyeli-
tis virus (TMEV) acts as a switch to stimulate pro-
grammed –1 ribosomal frameshifting (PRF) during
infection. Here, we present the X-ray crystal struc-
ture of TMEV 2A and define how it recognises the
stimulatory RNA element. We demonstrate a critical
role for bases upstream of the originally predicted
stem–loop, providing evidence for a pseudoknot-
like conformation and suggesting that the recogni-
tion of this pseudoknot by beta-shell proteins is a
conserved feature in cardioviruses. Through exam-
ination of PRF in TMEV-infected cells by ribosome
profiling, we identify a series of ribosomal pauses
around the site of PRF induced by the 2A-pseudoknot
complex. Careful normalisation of ribosomal profil-
ing data with a 2A knockout virus facilitated the
identification, through disome analysis, of ribosome
stacking at the TMEV frameshifting signal. These ex-
periments provide unparalleled detail of the molec-
ular mechanisms underpinning Theilovirus protein-
stimulated frameshifting.
INTRODUCTION
Cardioviruses are a diverse group of picornaviruses that
cause encephalitis, myocarditis and enteric disease in a va-
riety of mammalian hosts including rodents, swine and hu-
mans (1). The Cardiovirus B or Theilovirus species com-
prises several isolates including Sikhote-Alin virus (2), rat
theilovirus and Theiler’s murine encephalomyelitis virus
(TMEV), all of which are genetically distinct from the Car-
diovirus A species encephalomyocarditis virus (EMCV) (3).
Within the Cardiovirus B species, TMEV has been exten-
sively characterised and serves as a mouse model for virus-
induced demyelination andmultiple sclerosis (4). Like all pi-
cornaviruses, TMEV replication is cytoplasmic and begins
with the translation of its single-stranded ∼8 kb positive-
sense RNA genome. The resultant polyprotein (L-1ABCD-
2ABC-3ABCD) is subsequently processed, mainly by the
virally encoded 3C protease (5,6).
Several ‘non-canonical’ translation events occur during
the production of the TMEV polyprotein. First, initiation
is directed by a type II internal ribosome entry site (IRES)
in the 5′ untranslated region (UTR) (7,8). Secondly, a co-
translational StopGoor ribosome ‘skipping’ event occurs at
the junction between the 2A and 2B gene products (9,10). In
this process, the peptidyl-transferase reaction fails between
the glycine and proline in a conserved D(V/I)ExNPG|P
motif, releasing the upstream L-1ABCD-2A product as
the ribosome continues translating the downstream 2BC-
3ABCD region. Note that in TMEV, however, the presence
of a 3C protease cleavage site near the start of the 2B pro-
tein appears to make the occurrence of StopGo function-
ally redundant (11,12). Thirdly, programmed –1 ribosomal
frameshifting (PRF) diverts a proportion of ribosomes out
of the polyprotein reading frame and into a short overlap-
ping ORF, termed 2B*, near the start of 2B. In TMEV this
ORF is only eight codons in length and the resulting trans-
frame product 2B* has just 14 amino acids (∼1.4 kDa), with
no established functional role (11). Thus it has been hypoth-
esised that in TMEV, the main function of PRFmay simply
be to downregulate translation of the enzymatic proteins en-
coded downstream of the frameshift site, particularly in the
late stages of infection (11).
PRF is common amongst RNA viruses, where it is used
as a translational control strategy to express gene products
in optimal ratios for efficient virus replication. Additionally,
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the utilisation of overlapping ORFs permits more informa-
tion to be encoded by a small genome. Our mechanistic un-
derstanding of PRF has been informed by the study of ex-
amples in hundreds of viruses (reviewed in refs 13–15). Gen-
erally, PRF involves two elements within the viral messen-
ger RNA (mRNA). A heptameric shift site or ‘slippery se-
quence’ of the form X XXY YYZ (where XXX represents
any three identical nucleotides or certain other triplets such
as GGU, YYY represents AAA or UUU, and Z is any nu-
cleotide except G) (16) is located 5––9 nucleotides upstream
of a structured RNA ‘stimulatory element’ (usually a stem-
loop or pseudoknot) that impedes the progress of the elon-
gating ribosome, such that the ribosome pauses with the
shift site in the decoding centre (17–19). This can facilitate
a change of reading frame if the codon-anticodon interac-
tions of the P-site and A-site tRNAs slip and recouple in
the −1 frame (XXY → XXX and YYZ → YYY, respec-
tively) during resolution of the stimulatory element. For
any given system, such PRF generates a fixed ratio of prod-
ucts set by parameters that include the energetics of codon-
anticodon pairing at the shift site, the conformational flex-
ibility of the stimulatory element and the resistance of this
element to unwinding by the ribosomal helicase (20,21). In
cardioviruses, however, PRF exhibits some intriguingmech-
anistic exceptions. First, the conserved G GUU UUU shift
site is located 13––14 nucleotides upstream of the stimula-
tory stem-loop, seemingly too far away to position the shift
site in the decoding centre during a pause. Secondly, the vi-
ral 2A protein is required as a trans-activator of frameshift-
ing in cells and in vitro (11,22–24) which permits temporally
controlled, variable-efficiency frameshifting related to the
amount of 2A protein in the cell during infection. To date,
cardioviruses present one of only two known examples of
protein-stimulated frameshifting, along with porcine repro-
ductive and respiratory syndrome virus (PRRSV) and other
arteriviruses (family Arteriviridae), where a complex of vi-
ral nsp1 and host poly(C) binding protein stimulates PRF
(25–27).
Our previous investigations of protein-stimulated
frameshifting in EMCV and TMEV have revealed that the
viral 2A protein acts in complex with a stem-loop down-
stream of the slippery sequence, and that this interaction
can be disabled by mutating either a conserved cytosine
triplet in the loop or a pair of conserved arginine residues
in the protein (11,22,23). More recently, we solved the
structure of EMCV 2A, revealing a novel protein fold
that permits binding to both the stem-loop and to ribo-
somal RNA with high affinity (28). However, 2A protein
sequences are highly divergent within cardioviruses, and
the TMEV protein shares only ∼27% pairwise amino acid
sequence identity with its EMCV orthologue. Additionally,
the stem-loop that comprises the stimulatory element in
TMEV is significantly more compact than the equivalent
structure in EMCV. Here we present the X-ray crystal
structure of TMEV 2A and investigate the interaction
with its cognate RNA using a variety of biochemical
and biophysical techniques. We define a minimal TMEV
stimulatory element necessary for 2A binding and show
that the protein forms a 1:1 RNA-protein complex with
nanomolar affinity. We provide evidence that the alter-
native pseudoknot-like conformation recently described
for the EMCV stimulatory element (28) is also likely to
be present in TMEV and other cardioviruses. Finally, we
use metabolic labelling and ribosome profiling to study
2A-stimulated frameshifting and translation of the TMEV
genome at sub-codon resolution in infected cells. Together,
this body of work defines the molecular basis of Theilovirus
protein-stimulated frameshifting, one of the most efficient
frameshifting events known in nature.
MATERIALS AND METHODS
Protein expression and purification
TMEV 2A cDNA was amplified by PCR from plasmid
pGEX6P2-based constructs (23) (F 5′ AATTCATATG
AATCCCGCTTCTCTCTACCGC 3′; R 5′ AATTGGAT
CCTTATTAGCCTGGGTTCATTTCTACATC 3′) and
cloned into pOPT3G (29) to introduce a 3C protease-
cleavable N-terminal GST tag. Recombinant protein was
produced in Escherichia coli BL21(DE3) pLysS cells. Cul-
tures were grown in 2× TY broth supplemented with
100 g/ml ampicillin (37◦C, 210 rpm). Expression was
induced at A600 of ∼1 with 1.0 mM isopropyl -D-1-
thiogalactopyranoside (IPTG) and continued overnight
(210 rpm, 21◦C, 16 h). Bacteria were pelleted (4000 × g,
4◦C, 20 min), washed in cold PBS and stored at –20◦C.
Cells from four litres of culture were thawed in 200 mL ly-
sis buffer (50 mM Tris (HCl) pH 7.4, 500 mM NaCl, 0.5
mM MgCl2, 5.0 mM DTT, 0.05% w/v Tween-20 supple-
mented with 50 g/ml DNase I and EDTA-free protease
inhibitors) and lysed using a cell disruptor (24 kPSI, 4◦C).
The insoluble fraction was pelleted by centrifugation (39
000 × g, 40 min, 4◦C) and discarded. Supernatant was in-
cubated (2 h, 4◦C) with 4.0 ml of Glutathione Sepharose 4B
resin (GE Healthcare) that had been pre-equilibrated in the
same buffer. Protein-bound resin was washed three times by
centrifugation (600 × g, 10 min, 4◦C) and re-suspension in
150 mL wash buffer (50 mM Tris (HCl) pH 7.4, 500 mM
NaCl, 5.0 mM DTT). Washed resin was transferred to a
gravity column and protein was eluted in batch with 20 mL
wash buffer supplemented with 25 mM reduced glutathione
(1 h, 4◦C). GST-tagged 3C protease was added to the eluate
(10g/ml, prepared in-house) and themixture was dialysed
(3K molecular weight cut-off (MWCO), 4◦C, 16 h) against
2 l wash buffer to remove the glutathione. Dialysed pro-
teins were then re-incubated with Glutathione Sepharose
4B resin (as above; 2 h, 4◦C) to remove the cleaved GST
and GST-3C protease. The flow-through was subjected to
heparin-affinity chromatography to remove nucleic acids.
Samples were loaded on a 10 ml HiTrap Heparin column
(GE Healthcare) at 2.0 ml/min, washed with two column
volumes of buffer A (50 mM Tris (HCl) pH 7.4, 500 mM
NaCl, 1.0 mM DTT and eluted with a 0% → 100% gradi-
ent of buffer B (50 mM Tris (HCl) pH 8.0, 1.0 M NaCl, 1.0
mM DTT) over 20 column volumes. After removal of nu-
cleic acids, protein became aggregation-prone and precip-
itated at low temperatures, therefore all subsequent steps
were performed at 20◦C. Fractions corresponding to the
2A peak were pooled and concentrated using an Amicon®
Ultra centrifugal filter unit (10K MWCO, 4000 × g) prior
to size exclusion chromatography (Superdex 75 16/600 col-
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Purity was assessed by 4–20% gradient SDS-PAGE, and
protein identity verified by mass spectrometry. Purified pro-
tein was used immediately for crystallisation trials or was
concentrated (∼4.4 mg/ml, 282 M), snap-frozen in liquid
nitrogen and stored at –80◦C.
Size-exclusion chromatography coupled to multi-angle laser
scattering (SEC-MALS)
For studies of the TMEV 2A protein in isolation, a Su-
perdex 75 increase 10/300GL column (GEHealthcare) was
equilibratedwith 20mMTris (HCl) pH7.5, 1.0MNaCl (0.4
ml/min flow, 25◦C). Per experiment, 100 l of protein was
injected at concentrations of 3.1, 0.8 and 0.38 mg/ml (mo-
lar concentrations of 200, 51.5 and 24.5 M, respectively).
The static light scattering, differential refractive index, and
the UV absorbance at 280 nmwere measured byDAWN 8+
(Wyatt Technology), Optilab T-rEX (Wyatt Technology),
and Agilent 1260 UV (Agilent Technologies) detectors. The
corresponding molar mass from each elution peak was cal-
culated using ASTRA 6 software (Wyatt Technology) using
the differential refractive index and a dn/dc value of 0.186
to calculate the protein concentration. For studies of 2A-
RNA complexes, samples were recovered directly from the
ITC cell after confirmation of binding and concentrated to
an A280 of ∼3.1 prior to injection of 100 ul onto a Superdex
75 increase 10/300 GL column pre-equilibrated in 50 mM
Tris (HCl) pH 7.4, 200 mM NaCl (0.4 ml/min flow, 25◦C).
Data were recorded as above, and to estimate the relative
contributions of protein and RNA to molar mass, a protein
conjugate analysis was performed within ASTRA 6, using a
protein dn/dc value of 0.186 and an RNA (modifier) dn/dc
value of 0.168. Prior to this analysis, extinction coefficients
(at 280 nm) were determined experimentally from protein-
only and RNA-only peaks using the ‘UV extinction from
RI peak’ method in ASTRA 6.
Protein crystallization
Purified TMEV 2A was concentrated to 4.38 mg/ml in 50
mM Tris (HCl) pH 7.4, 1.1 M NaCl, 1.0 mMDTT. Sitting-
drop vapor diffusion experiments were set up in 96-well
MRC plates with 80 l reservoir solution, 200 nl protein
and 200 nl crystallization buffer. Diffraction-quality crys-
tals grew in 0.2MKBr, 0.2M potassium thiocyanate, 0.1M
sodium cacodylate pH 6.5, 3% (w/v) poly- -glutamic acid
200–400 and 10% (w/v) PEG-MME 2000. Crystals were
harvested in nylon loops and cryo-protected by removal
from the mother liquor through a 0.5 l layer of crystal-
lization buffer that had been supplemented with 20% (v/v)
glycerol, prior to flash-cooling by plunging into liquid ni-
trogen.
X-ray data collection, structure determination, refinement
and analysis
Datasets of 900 images (Supplementary Table S1) were
recorded from two crystals at beamline I04-1, Diamond
Light Source on a Pilatus 6M detector (Dectris), using 47%
transmission, an oscillation range of 0.2◦ and an exposure
time of 0.2 s per image. Data were collected at a wave-
length of 0.9159 Å and a temperature of 100 K. Reflec-
tions were indexed and integrated with DIALS (30) (high-
est resolution crystal) or XDS (31) (structure determina-
tion crystal) and data were scaled and merged with AIM-
LESS (32) within theXia2 data reduction pipeline (33). Res-
olution cut-off was decided by a CC1/2 value ≥0.5 and an
I/(I) ≥2.0 in the highest resolution shell (34). The struc-
ture was solved by single-wavelength anomalous dispersion
(SAD) analysis of the structure determination crystal, us-
ing anomalous signal from bromine present in the crys-
tallisation buffer. SAD phasing was performed using au-
toSHARP (35), implementing SHELXD for substructure
determination (36), SHARP for density modification (35)
and ARP/wARP (37) for automated model building. This
placed 123 residues out of 133 (92%) in the single chain that
comprised the asymmetric unit of the cubic P213 cell. This
preliminarymodel was subsequently used as amolecular re-
placement search model to solve a higher resolution dataset
(highest resolution crystal) using Phaser (38). This model
was then subjected to several rounds of manual adjustment
using COOT (39) and refinement with phenix.refine (40).
Upon completion of model building, ISOLDE (41) was
used to improve model geometry and resolve clashes prior
to a final round of refinement using phenix.refine. Mol-
Probity (42) was used to assess model geometry including
Ramachandran outliers, bad rotamers and mainchain ge-
ometry deviations throughout the refinement process. For
the electrostatic potential calculations, PDB2PQR (43) and
PROPKA were used to estimate protein pKa values and
assign partial charges. Electrostatic surface potentials were
calculated using APBS (44). Relative solvent-accessible sur-
face areas per residue were calculated using GetArea (45)
and crystallographic interaction interfaces were assessed
using PDBePISA (46). Structural figures depicting crys-
tallographic data (cartoon, stick and surface representa-
tions) were rendered in PyMOL (Schrödinger LLC). The
representation of surface conservation was generated using
ConSurf (47).
Nucleotide and protein sequence alignments
The Logo plot of nucleotide sequence conservation
at the PRF region was generated from a selection of
divergent isolates (Cardiovirus A – M81861, M22457,
KP892662, LC585221, KC310737, JX257003; Car-
diovirus B––EU542581, M20301, MF172923, MF352420;
Cardiovirus D––EU376934; Cardiovirus E, F and
unassigned––KY432928, KY432930, KY855434,
KF823815) with WebLogo 2.8.2 (48) using the default
parameters. For 2A protein sequence alignments, the
match > align tool in UCSF Chimera (49) was first used to
generate a seed alignment based on superposed structures
of EMCV and TMEV 2A, prior to the subsequent align-
ment of other selected divergent TMEV-like (MF352420,
M20301, MF172923, EU542581, EU376394, KY432930,
KY432928, KF823815, KY855434) and EMCV-like
(LC585221, KP892662, M81861, M22457, JX257003,
KC310737) 2A sequences. JalView (50) was used to visu-
alise the alignment, calculate the consensus sequence and
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Electrophoretic mobility shift assay (EMSA)
RNA oligonucleotides (IDT) were reconstituted in distilled
water. A 5′ Cy5 fluorescent label was incorporated using
the 5′ EndTag kit (Vector Labs) according to the manufac-
turer’s instructions, prior to phenol:chloroform extraction,
ethanol precipitation and aqueous resuspension. Concen-
tration of RNA was determined by measuring absorbance
at 260 nm. Binding reactions of 10 l contained 1.0 l 500
nM Cy5-RNA, 1.0 l TMEV 2A at concentrations of 280,
140, 70, 35, 17.5, 8.7, 4.4, and 2.2 M in 10mMHEPES pH
7.9, 1.0MNaCl, 5.0l 2× buffer (20mMTris (HCl) pH7.4,
80 mM NaCl, 4.0 mM magnesium acetate, 2.0 mM DTT,
10% v/v glycerol, 0.02% w/v bromophenol blue, 200 g/ml
porcine liver tRNA and 800 U /ml SUPERase-In [Invitro-
gen]) and 3.0 l distilled water. Final concentrations in the
binding reactions were therefore 50 nM RNA, 1× buffer,
∼140 mMNaCl and TMEV 2A at 28.0, 14.0, 7.0, 3.5, 1.75,
0.87, 0.44 and 0.22 M. All binding reactions were pre-
pared on ice, and samples were incubated at 37◦C for 20min
before analysis by non-denaturing 10% acrylamide/TBE
PAGE (25 min, 200 V constant). Gels were imaged with a
Typhoon FLA-7000 (GE) using the 635 nm laser/R670 fil-
ter.
Microscale thermophoresis (MST)
Synthetic RNA oligonucleotides (IDT) were labelled at the
5′ end with Cy5 as described above, prior to purification us-
ing Clean and Concentrator kit (Zymo). TMEV 2A in 10
mM HEPES pH 7.9, 1.0 M NaCl was diluted in 2× buffer
(20 mM Tris (HCl) pH 7.4, 80 mM NaCl, 4.0 mM magne-
sium acetate, 2.0 mM DTT) to a final concentration of 20
M. For the measurement, a series of 16 1:1 dilutions was
prepared and each ligand dilution was mixed with one vol-
ume of labeled TMEV RNA. Final concentrations in the
binding reactions were therefore 5.0 nM RNA, 1× buffer,
∼140 mM NaCl and TMEV 2A ranging from 0.0006 to
20 M. The reaction was mixed and the samples loaded
into Monolith NT.115 Premium Capillaries (NanoTem-
per Technologies). Measurements were performed using a
Monolith NT.115Pico instrument (NanoTemper Technolo-
gies) at an ambient temperature of 25◦C. Instrument pa-
rameters were adjusted to 5% LED power and medium
MST power. Data of two independently pipetted measure-
ments were analysed for fraction bound using initial fluores-
cence (MO.Affinity Analysis software, NanoTemper Tech-
nologies). The non-binding RNAs (namely TMEV 2 and 4)
were normalized using Prism 8.0.2 (GraphPad). Data was
plotted using Prism 8.0.2 (GraphPad) software.
Isothermal titration calorimetry (ITC)
ITC analyses were carried out at 25◦C using a Micro-
Cal PEAQ-ITC (Malvern Panalytical). RNAs and proteins
were dialysed (24 h, 25◦C) into buffer (50 mM Tris (HCl)
pH 7.4, 400 mMNaCl) before performing experiments. Fi-
nal concentrations of protein and RNA after dialysis were
determined by spectrophotometry (A280 and A260, respec-
tively), using theoretical extinction coefficients based on the
primary sequence of each component. RNA (60 M) was
titrated into protein (5 M) with 1× 0.4 l injection fol-
lowed by 12× 3.0 l injections. Control titrations of RNA
into buffer, buffer into protein and buffer into buffer were
also performed. Data were analyzed using the MicroCal
PEAQ-ITC analysis software (Malvern Panalytical) and
binding constants determined by fitting a single-site bind-
ing model.
In vitro transcription
For in vitro frameshifting assays, a 105 nt portion of
the TMEV genome containing the GGUUUUU shift site
flanked by 6 nt upstream and 92 nt downstream was cloned
into the dual luciferase plasmid pDluc at the XhoI/BglII
sites (51). The sequence was inserted between the Renilla
and firefly luciferase genes so that firefly luciferase expres-
sion is dependent on −1 PRF. Wild-type or derivative
frameshift reporter plasmids were linearized with FspI and
capped run-off transcripts generated using T7 RNA poly-
merase as described (52). Messenger RNAs were recovered
by phenol/chloroform extraction (1:1 v/v), desalted by cen-
trifugation through a NucAway Spin Column (Ambion)
and concentrated by ethanol precipitation. The mRNAwas
resuspended in water, checked for integrity by agarose gel
electrophoresis, and quantified by spectrophotometry.
Translation
Messenger RNAs were translated in nuclease-treated rab-
bit reticulocyte lysate (RRL) (Promega). Typical reactions
were composed of 90% (v/v) RRL, 20 M amino acids
(lacking methionine) and 0.2 MBq [35S]-methionine and
programmed with ∼50 g/ml template mRNA. Reactions
were incubated for 1 h at 30◦C. Samples were mixed with
10 volumes of 2 × Laemmli’s sample buffer, boiled for 3
min and resolved by SDS-PAGE. Dried gels were exposed
to a Storage Phosphor Screen (PerkinElmer), the screen
was then scanned in a Typhoon FLA7000 using the phos-
phor autoradiography mode. Bands were quantified using
ImageQuant™TL software. The calculations of frameshift-
ing efficiency (% FS) took into account the differential me-
thionine content of the various products and % FS was
calculated as % −1FS = 100 × (IFS/MetFS)/[(IS/MetS)
+ (IFS/MetFS)]. In the formula, the number of methion-
ines in the stop and −1 frameshift products are denoted by
MetS, MetFS respectively; while the densitometry values
for the same products are denoted by IS and IFS respec-
tively. All frameshift assays were carried out a minimum of
three times.
Cells and viruses
BSR (single cell clone of BHK-21 cells, speciesMesocricetus
auratus, provided by Polly Roy, LSHTM, UK) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM),
high glucose, supplemented with L-glutamine (1 mM), an-
tibiotics, and fetal bovine serum (FBS) (5%), at 37◦C and
5% CO2. Cells were verified as mycoplasma-free by PCR
(e-Myco plus Mycoplasma PCR Detection Kit, iNtRON
Biotechnology). Cells were seeded to achieve 80% conflu-
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in (23), based on GDVII isolate NC 001366 with three
nucleotide differences present in WT and mutant viruses
(G2241A, A2390G and G4437A; nt coordinates with re-
spect to NC 001366). All infections, except for plaque as-
says, were carried out at a MOI of 3 in serum-free media,
or media only for the mock-infected samples. After incuba-
tion at 37◦C for 1 h, inoculum was replaced with serum-free
media supplemented with FBS (2%), and infected cells were
incubated at 37◦C until harvesting or further processing.
Plaque assays
BSR cells in six-well plates at 90% confluence were inocu-
lated with serial dilutions of virus stocks for 1 h then over-
laid with 2 ml DMEM supplemented with L-glutamine (1
mM), antibiotics, FBS (2%), and carboxymethyl cellulose
(0.6%). Plates were incubated at 37◦C for 48 h then fixed
with formal saline and stained with 0.1% toluidine blue.
Western blots of 2A expression
BSR cells in 35 mm dishes were inoculated for 1 h at a MOI
of 3, and incubated at 37◦Cuntil 2, 4, 6, 8, 10 or 12 hpi. Cells
were washed with cold PBS and lysed in 200 l 1× radioim-
munoprecipitation assay (RIPA) buffer [50 mM Tris (HCl)
pH 8, 150 mM sodium chloride, 1% NP-40 substitute, 0.5%
sodium deoxycholate, 0.1% SDS] supplemented with Halt™
Protease Inhibitor Cocktail (1X). Samples were resolved by
4–20% gradient SDS-PAGE and transferred to 0.2 m ni-
trocellulose membranes. Membranes were blocked with 5%
(w/v) milk dissolved in PBS (1 h, 25◦C). Primary antibod-
ies were diluted in 5% (w/v) milk, PBS, 0.1% (v/v) Tween-
20 and incubated with membranes (1 h, 25◦C). After three
washes in PBS, 0.1% (v/v) Tween-20, membranes were in-
cubated with IRDye fluorescent antibodies in 5% w/v milk,
PBS, 0.1% (v/v) Tween-20 (1 h, 25◦C). Membranes were
washed three times in PBS, 0.1% (v/v) Tween-20 and rinsed
in PBS prior to fluorescent imaging with an Odyssey CLx
platform (LI-COR).Antibodies usedwere rabbit polyclonal
anti-2A (22) (1/1000); mouse monoclonal anti-GAPDH
(1/20 000, clone G8795, Sigma-Aldrich), goat anti-rabbit
IRDye 800 CW (1/10 000, LI-COR), and goat anti-mouse
IgM ( chain specific) IRDye 680RD (1/10 000, Li-Cor).
Metabolic labelling of infected cells
BSR cells in 24-well plates were infected at a MOI of 3
in a volume of 150l. After 1 h, the inoculum was re-
placed with DMEM containing 2% FBS (1ml) and cells
were incubated at 37◦C for 5, 7 or 9 h delineating the 8,
10 or 12 hpi timepoints respectively. At the set timepoint
post-infection, cells were incubated for 1 h in methionine-
and serum-free DMEM, then radiolabelled for 1 h with
[35S]-methionine at 100Ciml−1 (∼1100Cimmol−1) in
methionine-free medium. Cells were harvested and washed
twice by resuspension in 1ml ice-cold phosphate-buffered
saline (PBS) and pelleted at 13 000 g for 2 min. Cell pellets
were lysed in 40l 4× SDS–PAGE sample buffer and boiled
for 5min before analysis by SDS–PAGE.Dried gels were ex-
posed to X-ray films or to phosphorimager storage screens.
Image analysis was carried out using ImageQuantTL 7.0 to
quantify the radioactivity in virus-specific products.
Bands which were quantifiable for all three viruses (Sup-
plementary Table S3) were carried forward for normal-
isation by methionine content and then by an average
of the quantifiable proteins upstream of the frameshift
site as a loading control. Bands in the WT and SS
lanes were normalised by the counterpart bands in the
M3 lane to control for differences in protein turnover.
Frameshift efficiency (%) is given by the equation 100× [1−
(downstream/upstream)], where downstream and upstream
represent the average of the fully normalised intensity val-
ues for proteins downstream and upstream of the frameshift
site, respectively.
Ribosome profiling library preparation
BSR cells in 9 cm2 dishes were inoculated in triplicate for
1 h at 37◦C at a MOI of 3, or media only for the mock-
infected samples. After inoculation, cells were incubated
in serum-free media supplemented with FBS (2%) at 37◦C
for 9 h. Cells were harvested and ribosome-protected frag-
ments (RPFs) purified and prepared for next-generation
sequencing as described (53), based on (54–56), with the
following modifications. The cycloheximide pre-treatment
was omitted from the harvesting protocol and cells were in-
stead washed with warm PBS before snap-freezing in liq-
uid nitrogen. RNase I (Ambion) was added to 300 l lysate
(∼12––18 g RNA) to final concentration 0.5 U/l (repli-
cate 1) or 2.5 U/l (replicate 2 and 3––higher concentration
to ameliorate incomplete trimming noticed in replicate 1),
and digestion inhibited after 45 min (room temperature) by
adding SUPERase-In RNase inhibitor (Invitrogen) to final
concentration 0.13 and 0.67 U/l, respectively. The range
of fragment sizes selected during polyacrylamide gel purifi-
cation before ligation to adapters was increased to 19–34
nt, and size ranges for post-ligation gels adjusted accord-
ingly. For replicate three samples, two gel slices were excised
per library, to purify monosome-protected (19–34 nt) and
broad spectrum (35–65 nt) fragments from the same lysate.
Depletion of ribosomal RNA was carried out solely by use
of the RiboZero Gold Human/Mouse/Rat kit (Illumina).
Adapter sequences were based on the TruSeq small RNA
sequences (Illumina), with an additional seven random nu-
cleotides at the 5′-end of the 3′-adapter and the 3′-end of the
5′-adapter, to reduce the effects of ligation bias and enable
identification of PCR duplicates. For the broad-spectrum
libraries only the 3′-adapter contained the 7 random nu-
cleotides. Libraries were deep sequenced on the NextSeq
500 platform (Illumina), and data made publicly available
on ArrayExpress under accession numbers E-MTAB-9438
and E-MTAB-9437.
Ribosome profiling data analysis
Adapter sequences were removed and reads resulting
from RNA fragments shorter than 19 nt discarded using
fastx clipper (version 0.0.14, parameters: -Q33 -l 33 -c -n
-v). Sequences with no adapters and those which consisted
only of adapters were discarded. PCR duplicates were re-
moved using awk, and the seven random nucleotides origi-
nating from the adapters were trimmed from each end of the
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reference databases using bowtie1, allowing one mismatch
and reporting only the best alignment (version 1.2.3, pa-
rameters: -v 1 –best), in the following order: rRNA, virus
genome (vRNA), mRNA, ncRNA, mtDNA and gDNA.
Quality control analysis indicated some contamination of
replicate 2 libraries with E. coli RNA (BL21). These reads
do not exhibit the expected features of genuine RPFs,
however, indicating that the contamination occurred af-
ter lysates were harvested and thus they do not affect our
conclusions. Reads were re-mapped with the addition of
a BL21 reference database (CP047231.1) before vRNA,
to remove these reads. The rRNA database comprised
GenBank accession numbers NR 003287.2, NR 023379.1,
NR 003285.2 and NR 003286.2. The mRNA database was
compiled from the 36827M. auratusGenBank RefSeq mR-
NAs available on 17 November 2017, after removing tran-
scripts with annotated changes in frame. The ncRNA and
gDNA databases are from M. auratus Ensembl release 90
(genome assembly 1.0). Viral genome sequences were ver-
ified by de novo assembly with Trinity (version 2.9.1), and
reversion rates for mutated bases were verified as below
0.5%. For the broad-spectrum dataset, reads with no de-
tected adapter were not discarded by fastx clipper, PCR
duplicates were not removed, and two mismatches were al-
lowed during bowtie1 mapping, except to BL21 E. coli, for
which one mismatch was allowed.
To visualise RPF distribution on the viral genome, the
number of reads with 5′-ends at each position was counted
and divided by the total number of positive-sense vRNA
and host mRNA reads for that library, to normalise for
library size and calculate reads per million mapped reads
(RPM). For plots covering the entire virus genome, a sliding
window running mean filter of 15 nt was applied. To gen-
erate the plot of WT and SS data normalised by M3 data,
UTRs plus a small buffer (7 nt at the 5′-end of the CDS and
27 nt at the 3′-end) were excluded and the result of the 15
nt running mean at each position on the WT or SS genome
was divided by the 15 nt running mean at the correspond-
ing position on the M3 genome. This avoided any instances
of division by zero. Only positive-sense reads were used,
and library pairs for normalisation were allocated accord-
ing to replicate number. For the broad-spectrum dataset,
guided by the length distribution and phasing plots, reads of
lengths 51–52, 54–55 and 57–64 nt were selected for analysis
as potential ‘disome-protected fragments’, and the denom-
inator for normalisation of disome-protected read densities
to RPM was calculated using only reads of these lengths.
For all plots of read distribution on the viral genome, a +12
nt offset was added to the 5′-end coordinate of the read
before plotting, to reflect the inferred position of the ri-
bosomal P site. For disome-protected fragments, this rep-
resents the position of the P site of the colliding ribo-
some. For plots in the main text showing data from only
one replicate, replicate 3 was used. Relative adaptiveness
values for sense codons to the cellular tRNA pool were
downloaded from the Species-Specific tRNA Adaptive In-
dex Compendium (57), for Cricetulus griseus as a proxy
for M. auratus, on 3 August 2020. For the phasing and
length distribution quality control plots, only reads which
map completely within the CDSs of host mRNAs were
included.
Frameshift efficiency (%) is given by the equation 100 ×
[1 – (downstream/upstream)], where downstream and up-
stream represent the reads per kilobase per million mapped
reads (RPKM) values for the respective regions (genomic
coordinates: upstream 1368–3943; downstream 4577–7679)
after normalisation ofWT and SS densities byM3. The per-
centage of reads in each phase in the upstream, transframe,
and downstream regions relative to the 2B* frameshift
site were determined using reads with inferred P site posi-
tions in the following ranges: upstream 1098–4211, trans-
frame 4247–4273, downstream 4308–7946. Phases were des-
ignated relative to the polyprotein reading frame.
RESULTS AND DISCUSSION
Structure of TMEV 2A reveals a beta-shell protein with a
divergent RNA-binding surface
TMEV 2A protein was purified following recombinant ex-
pression as a GST fusion in E. coli (Figure 1A). After cleav-
age of the GST tag and removal of contaminating nucleic
acids by heparin affinity chromatography, high-salt con-
ditions were required to prevent aggregation and main-
tain solubility. Under optimised conditions, size-exclusion
chromatography coupled to multi-angle light scattering
(SEC-MALS) revealed the protein to be predominantly
monomeric (Figure 1B, peak 2) with an observed Mw of
16,683 Da compared to a theoretical mass of 15 941 Da,
as calculated from the primary sequence. A small propor-
tion of trimers was also present (Figure 1B, peak 1: ob-
served mass of 46 867 Da versus theoretical mass of 47 823
Da). We crystallised the protein but were unable to solve
the structure by molecular replacement using the crystal
structure of the closest homologue, EMCV 2A (28), as a
search model. Instead, we obtained experimental phases
via bromine derivatisation and determined the structure
by single-wavelength anomalous dispersion analysis. The
asymmetric unit of the cubic cell contained a single copy of
2A, which was refined to 1.9 Å resolution (Supplementary
Table S1, Figure 1C). Interpretable electron density was vis-
ible for 2A residues 1–126, with a short G-4P-3L-2G-1S0 N-
terminal extension that resulted from 3C protease cleavage
of the GST tag. In the crystalline lattice these residues me-
diate contacts between symmetry-related molecules, consis-
tent with recombinant 2A forming trimers at high concen-
trations (Supplementary Figure S1). These residues project
away from the globular TMEV domain and lack regular
secondary structure, suggesting that they will be flexible at
lower concentrations of 2A in solution where monomers
predominate (Figure 1B). Since tag-derived residues medi-
ate the inter-subunit contacts, the 2A trimerisation interface
that we observe in crystallo is unlikely to be physiologically
relevant. However, we cannot exclude the possibly that al-
ternate protein-protein interfaces may exist at physiological
salt.
The structure of TMEV 2A reveals a globular 33
fold, with a similar ‘beta-shell’ architecture to EMCV 2A
(C backbone RMSD of 2.65 Å over 130 residues) (28). An
extensive curved antiparallel six-stranded beta sheet packs
against two alpha helices on the concave surface of the
sheet, whilst the loops between adjacent beta strands project
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Figure 1. TMEV 2A adopts the beta-shell fold. (A) SDS-PAGE analysis of TMEV 2A after Ni-NTA, heparin affinity and size-exclusion chromatography.
The gel was stained with Coomassie blue. (B) SEC-MALS analysis of 2A in high-salt buffer at 3.1 mg/ml. The differential refractive index curve (blue)
is shown and the weight-averaged molar masses for indicated peaks are listed. (C) X-ray crystal structure of TMEV 2A in two orthogonal views. N- and
C- termini are indicated, and amino acids introduced as a result of the cloning strategy are labelled in purple. <Inset > Electrostatic surface potential
calculated at pH 7.4, coloured between +3 (blue) and −3 kT/e– (red). (D) Locations of mutations are colour-coded and shown as sticks: M1 (K24A /
R28A, green); M2 (R45A, blue); M3 (R85A / R95A, red); M4 (K90A / K91A, pink). (E) Superposition of TMEV 2A (blue) with EMCV 2A (orange).
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(pI∼ 9.4) and most of the contributing lysine, arginine and
histidine residues are solvent-exposed. At physiological pH
the protein will thus have a positive electrostatic surface po-
tential across the convex face of the beta sheet, surrounding
loops and the N-terminal end of helix 1, suggesting a pu-
tative RNA-binding surface (Figure 1C). This is supported
by a previous biochemical analysis of TMEV 2A function,
in which we made several point mutations of conserved ba-
sic residues and assessed their ability to stimulate PRF (23)
(Figure 1D). The M3 mutant (R85A/R87A, termed ‘2A-
mut’ in Napthine et al., 2019) was found to completely in-
hibit frameshifting, and the M1 mutant (K24A/R28A) was
found to reduce it by approximately four-fold. BothM3 and
M1 are in surface loops on either side of this large, positively
charged beta sheet, consistent with a role for this face of
the protein in forming electrostatic interactions with the ri-
bose phosphate backbone of the PRF stimulatory element.
In contrast, M2 (R45A) had no effect – indeed most of this
residue is buried (only ∼11.6% of the residue’s surface area
being solvent-accessible) and it likely plays a structural role
in stabilising packing of helix 1 against the underside of
the central sheet. Perhaps surprisingly, M4 (K90A/K91A)
also had no effect, despite these residues being located in the
same positively charged loop as the essential R85 and R87.
This demonstrates that charge alone is not sufficient to drive
RNA binding, and the reliance on arginine may reflect a re-
quirement for a more complex network of bidentate or bi-
furcated bonding interactions between the side chain guani-
dinium groups and backbone or base atoms in the RNA.
Despite low sequence identity, the overall fold of TMEV
2A is similar to EMCV 2A (Figure 1E). The most func-
tionally important part of EMCV 2A is the ‘arginine loop’
between strands 5 and 6 – necessary for PRF (22),
RNA binding (28) and nuclear localisation (58). The two
arginines in this loop (R95/R97 in EMCV 2A; R85/R87 in
TMEV 2A) are amongst the only surface-exposed residues
that are completely conserved across both species of car-
diovirus. (Figure 2A). Structurally, this loop adopts an al-
most identical conformation, consistent with mutagene-
sis data suggesting that they are functionally equivalent
(22,23). However, there are also some key differences be-
tween the two 2A orthologues (Figure 1E). The loop re-
gion between the end of 1 and the start of 4 is much
longer in EMCV 2A. This loop, and the N-terminal end of
1, are two of three regions that contribute to the RNA-
binding surface in EMCV 2A (28). These two regions are
not conserved in TMEV 2A (Figure 2B): the backbone ge-
ometry is different, and, with the exception of K63 and
R45, there are no chemically equivalent side chains in the
vicinity that could form similar interactions. To investi-
gate this further, we prepared variants of TMEV 2A con-
taining point mutations (R85A/R87A, K63A, K83A and
K53A/H56A; Supplementary Figure S2A) and tested their
ability to bind stimulatory element RNA (Supplementary
Figure S2B). Only the R85A/R87A protein showed a sig-
nificant defect compared to wild-type protein, confirming
the unique importance of this conserved arginine loop. Be-
yond this, the RNA binding surface in TMEV 2A likely dif-
fers from EMCV 2A, perhaps involving additional residues
on the surface of the beta sheet that are only conserved
amongst Theilovirus isolates (e.g. R7, D9, K24, H26; Fig-
ure 2C). This is supported by a reduction in PRF seen with
the M1 (K24A) mutant (23).
The conservation at the C-terminus of the protein (Figure
2A) is concentrated in the D(V/I)ExNPG motif required
for StopGo peptide release between 2A and 2B gene prod-
ucts in other cardioviruses (9,10). As expected, this motif is
unstructured in both proteins, and if we consider only the
ordered amino acids, we observe some of the largest struc-
tural differences (Figure 1E). In EMCV 2A, the shorter 2
helix leads to a more pronounced curvature of the central
beta sheet, and the C-terminus forms a short 7 strand that
packs against 3. Conversely, in TMEV 2A, the 2 helix
continues with a pronounced 90◦ kink until the end of the
protein. This has consequences for the structure of the puta-
tive YxxxxL motif at the C-terminus that has previously
been reported to sequester eIF4E in a manner analogous
to 4E-BP, thereby disabling cap-dependent translation of
host mRNA (58). In TMEV 2A, the first tyrosine residue
of this motif (Y119) is located on the buried side of the 2
helix (with only approximately 4.0% of the residue’s surface
area being solvent accessible) and is therefore not available
to interact with eIF4E. A second tyrosine (Y120) is more
exposed (∼26.7% of the residue’s surface area being solvent
accessible), but given the local secondary structure, it is un-
likely that L124 and I125 would be able to interact with
eIF4E in the same way as 4E-BP without a significant con-
formational change (Figure 2D). In EMCV 2A, the puta-
tive YxxxxL motif is not helical, instead forming a more
extended backbone (28). Superposition of this region re-
veals that this motif is not structurally conserved between
2A orthologues (Figure 2E). Therefore, the interaction with
eIF4Emust either involve other parts of the protein or must
be accompanied by significant structural rearrangement of
the 2 helix of TMEV.
A minimal 37 nt pseudoknot in the viral RNA is required for
2A binding
The PRF stimulatory element in TMEV consists of a stem-
loop (seven base-pair stem and 10 nucleotide loop) lo-
cated 14 nucleotides downstream from the shift site (Fig-
ure 3A). This is more compact than the equivalent element
in EMCV, which has a 21 nt loop that may contain an ad-
ditional stem (22,28). However, in both viruses, three con-
served cytosines in the loop are essential for 2A binding
(22,23). To determine the minimal RNA element necessary
for interaction with TMEV 2A, we prepared a series of syn-
thetic RNA constructs (Figure 3B) and assessed 2A binding
by electrophoretic mobility shift assays (EMSA; Figure 3C)
and microscale thermophoresis (MST; Figure 3D).
Binding of 2A was generally high affinity, with dissoci-
ation constants in the sub-micromolar range. (Figure 3D).
Truncation of either the shift-site (TMEV 1,KD = 484 ± 90
nM), the 3′ extension (TMEV 3, KD = 495 ± 110 nM) or
both (TMEV 6, KD = 280 ± 40 nM) had little effect on 2A
binding. Shortening the loop by three nucleotides (TMEV
5, KD = 615 ± 89 nM) slightly reduced the affinity, how-
ever removal of the 5′ extension (TMEV 2, TMEV 4) com-
pletely abolished 2A binding, even though the stem–loop
in TMEV 4 is predicted to be intact, and the three essen-
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Figure 2. Comparison of the TMEV 2A structure with the EMCV orthologue reveals a divergent RNA-binding surface and C-terminal region. (A)
Amino acid sequence alignment of selected divergent TMEV-like (upper) and EMCV-like (lower) cardiovirus 2A protein sequences, guided by the structural
alignment of EMCVandTMEV2Aproteins. Known secondary structures are indicated above the corresponding sequence for EMCVandTMEVproteins.
N- and C-terminal residues not observed in the structures are greyed out. Conservation is highlighted in blue. Local motifs of functional significance are
highlighted and annotated. (B) Comparison of RNA-binding residues in EMCV 2A (28) (beige) with equivalent surface in TMEV 2A (pale blue). Residues
involved in RNA binding come from three regions of the EMCV protein as indicated in (A) (shown as red, crimson and brown sticks). TMEV residues
that may be functionally-equivalent are shown as sticks (cyan). (C) Surface of TMEV 2A, coloured by conservation from highly conserved (purple) to
variable (teal) amongst the divergent TMEV-like sequences listed in A. Highly conserved, surface-accessible residues are labelled and shown as sticks. (D)
Comparison of the YxxxxL bindingmotif in 4E-BP1 and putative motif in TMEV 2A. The crystal structure of the complex between eIF4E and 4E-BP1 is
shown (green and blue, respectively) with 2A (pale blue) docked via least-squares superposition of the YxxxxL motif. A local surface cutaway, removing
a section of 3 (dashed lines), shows the buried location of Y119. Inset: Contrast between the two different helical conformations of the putative 2A
YxxxxL motif and the 4E-BP1 YxxxxL motif, in a compact -helical conformation. (E) Conformational differences between the C-terminal putative
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Figure 3. 2A recognises a minimal 37 nt stimulatory element in the viral RNA. (A, B) Sequences and schematic diagrams of the TMEV 1–6 constructs
used to assay 2A binding. (C) EMSA analysis conducted with 50 nM Cy5-labelled RNAs and 2A concentrations between 0 and 28 M. Following non-
denaturing electrophoresis, fluorescence was imaged using a Typhoon scanner. (D) MST binding curves and apparent KD values using the same constructs.
(E) Experiment showing the effects of titrating excess short RNAs (TMEV 1–6) as competitors into an in vitro frameshift reporter assay. The concentrations
of the reporter mRNA and 2Awere kept constant in the RRL and short RNAs were added in 10- and 100-fold molar excess relative to the reporter mRNA,
as indicated. Translation products were visualised by using autoradiography, and % frameshifting was calculated following densitometry and correction
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small RNAs are adopting conformations relevant to PRF,
we performed competition experiments. A dual-luciferase-
based reporter mRNA containing the TMEV shift site and
stimulatory element was prepared and designed such that 0-
frame and −1-frame products would be easily distinguish-
able by SDS-PAGE following in vitro translation in rabbit
reticulocyte lysates (23). In the presence of 2A, PRF oc-
curred efficiently (∼57%; Figure 3E), but inclusion of a mo-
lar excess of the small RNA would be predicted to reduce
PRF efficiency if the competitor RNAwere to sequester 2A
from the reporter mRNA. In line with the EMSA assays,
TMEV 3 and TMEV 6 both efficiently competed with the
reporter mRNA, reducing PRF to 38% and 21%, respec-
tively. TMEV 1 was able to compete to a lesser extent, re-
ducing PRF to 44%, whilst RNAs lacking the 5′ extension
(TMEV 2, TMEV 4) were unable to compete (Figure 3E).
We have recently shown that the 5′ extension is also im-
portant for 2A binding in EMCV, where it likely forms the
second stem of an RNA pseudoknot via interaction with
the CCC loop motif (28). However, given that the equiva-
lent loop sequence is 11 nt shorter in TMEV, it was unclear
whether this alternate conformation would be topologically
possible for the more compact RNA element. Neverthe-
less, an alignment of cardiovirus RNA sequences that direct
PRF shows that, in addition to the cytosine triplet, there are
several nucleotides in the 5′ extension that are completely
conserved in all isolates (Figure 4A, Supplementary Figure
S3). To investigate this in more detail, we truncated the 5′
extension one nucleotide at a time (Figure 4B) and assessed
2A binding by EMSA (Figure 4C). Removal of the first six
nucleotides of the 5′ extension (CAGCCA; TMEV 7–9) had
no dramatic effect on 2A binding, however removal of nu-
cleotides from the conserved CAAGG motif progressively
reduced binding until it was undetectable (TMEV 12). To
explore this further, we made point mutations and assessed
their effects in a frameshift reporter assay (Figure 4D). As
expected, loop mutations C36G or C38G abolished PRF.
However, frameshifting in the C38G background was re-
stored by introducing a G17C mutation in the 5′ extension,
demonstrating the necessity for a base pair between posi-
tions 17 and 38. The importance of this alternate confor-
mation for 2A recognition was verified by EMSA analysis
(Figure 4E). In RNA TMEV 9, which comprises the mini-
mal functional element as defined by the deletion analysis,
individual mutation of either C38 or G17 completely abro-
gated 2A binding. An unrestrainedRNA folding simulation
(59) identified a pseudoknot-like conformation consistent
with the biochemical data, including a base pair between
G17 and C38 (Figure 4F). This is consistent with our evi-
dence for a pseudoknot-like conformation in the EMCV se-
quence that is selectively recognised by 2A (28). Whilst the
double C38G + G17C mutant could rescue PRF in our in
vitro reporter assay, it did not restore 2A binding by EMSA,
either in the background of TMEV 9 (Figure 4E) or the
longer TMEV 1 RNA (data not shown). It is possible that
the double mutant forms a topologically equivalent con-
former that is either less stable and/or binds 2A with lower
affinity. Thus, whilst this RNA is still able to stimulate PRF,
the association does not persist for the necessary timescales
to permit observation in a dissociative technique such as
EMSA.
To assess the binding affinity and stoichiometry in solu-
tion with unlabelled RNA, we carried out isothermal titra-
tion calorimetry (ITC) experiments with TMEV 6 and 2A
protein. To prevent protein aggregation in the ITC cell, it
was necessary to perform the titration at 400 mMNaCl. In-
creasing the salt concentration had only a slight effect on 2A
binding as judged by EMSA (Figure 5A) and under these
conditions we observed a KD of 67 ± 7 nM and a ∼1:1 mo-
lar ratio of protein to RNA (Figure 5B and C). The large
contribution of H (−10.7 ± 0.13 kcal/mol) term to the
overall free energy of binding (−9.8 kcal/mol) is consistent
with an interaction mechanism driven by hydrogen bond or
electrostatic contact formation. To confirm the stoichiom-
etry in solution, we performed a SEC-MALS analysis of
the mixture retrieved from the ITC cell (Figure 5D). As ex-
pected, the two peaks correspond to an approximate 1:1
RNA-protein complex (early; Mw 33,570 Da observed vs.
27 105 Da expected) and excess free RNA (late;Mw 10,980
Da observed versus 11 164 Da expected).
Snapshots of translation in TMEV-infected cells by ribosome
profiling
We extended our examination of 2A-stimulated PRF by
analysing TMEV-infected cells using ribosome profiling,
a deep sequencing-based technique that gives a global
snapshot of the positions of translating ribosomes at sub-
codon resolution (55,60). In addition to WT virus, two
mutant viruses were employed. Virus SS has two synony-
mous mutations in the slippery sequence (G GUU UUU
toA GUG UUU) that prevent frameshifting (23,24). Virus
M3 has theWT slippery sequence, but contains theM3mu-
tations in the 2A protein described above (Figure 1D), ren-
dering it unable to bind to the PRF-stimulatory RNA stem-
loop (23).
BSR cells, a single-cell clone of theMesocricetus auratus
BHK-21 cell line, were selected for the ribosome profiling
due to their relative genetic homogeneity. Thus, we first ver-
ified in BSR cells several features of TMEV infection ob-
served in BHK-21 cells (11,23). The small-plaque pheno-
type previously observed for the SS and M3 mutant viruses
(22–24) was confirmed (Supplementary Figure S4A), and
expression of 2A was detectable from eight hours post-
infection (hpi) onwards. Levels increased up to 12 hpi, at
which point cytopathic effects become fairly extensive (Sup-
plementary Figure S4B).
Metabolic labelling experiments were carried out to
verify the occurrence of highly efficient frameshifting in
TMEV-infectedBSR cells. Viral proteins downstreamof the
frameshift site are only translated by ribosomes which have
not undergone frameshifting, as those that frameshift en-
counter a stop codon in the − 1 frame eight codons down-
stream of the shift site. Frameshift efficiency was estimated
from the ratio of downstream to upstream products (Fig-
ure 6A, Supplementary Figure S4C), normalised by the
frameshift-defective M3 mutant as a control (detailed in
Methods, and previously described in refs 11 and 61). The
mean WT frameshift efficiency was found to increase from
63% at 10 hpi to 78% at 12 hpi (Figure 6B, blue bars) (two-
tailed Welch’s t-test: t = −2.92, df = 2.80, P = 0.067) simi-
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Figure 4. A conserved AAGGmotif present in the 5′ extension is required for 2A binding. (A) Logo plot showing conservation of aligned cardiovirus RNA
sequences (see Supplementary Figure S3) spanning the experimentally defined minimal element. Asterisks indicate invariant nucleotides. (B) Schematic
diagrams of the TMEV 7–12 sequences used to assay 2A binding. (C) EMSA analysis conducted with 50 nM Cy5-labelled RNAs and 2A concentrations
between zero and 28 M. Following non-denaturing electrophoresis, fluorescence was imaged using a Typhoon scanner. (D) Frameshift reporter assays
showing that mutation of the loop CCCmotif inhibits frameshifting, but complementary mutations in the 5′ AAGGmotif that allow base pairing between
positions 17 and 38 restore frameshifting. (E) EMSA analysis showing attenuation of 2A binding to the minimal TMEV 9 RNA by introducing point
mutations to either the 5′ AAGG motif or loop CCC motif. (F) Hypothetical equilibrium between predicted stem-loop and alternate pseudoknot-like
conformations, colour-coded as in (A). The pseudoknot-like conformation involves a base-pair between G17 in the 5′ extension, and C38 in the loop
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Figure 5. 2A binds to the RNA stimulatory element with equimolar stoi-
chiometry and nanomolar affinity. (A) EMSA analysis showing the effects
of salt concentration (indicated) on RNA binding. Experiments were con-
ducted with 50 nM Cy5-labelled TMEV 6 and 2A concentrations between
zero and 28 M. Following non-denaturing electrophoresis, fluorescence
was imaged using a Typhoon scanner. (B) ITC isotherm for a titration of
TMEV 6RNA into 2A protein in the presence of 400 mMNaCl. (C) Bind-
ing curve from titration in (B), showing approximately 1:1 molar ratio and
nanomolar affinity. Inset:Histogram showing relative contributions ofH
and TS terms to the overall exergonic interaction. (D) SEC-MALS anal-
ysis of 2A-TMEV 6 RNA complex in buffer containing 200 mM NaCl.
The 280 nm UV absorbance trace is shown (green). Weight-averaged mo-
lar masses across the indicated peaks are listed, along with mass contri-
butions from the protein (blue) and RNA (pink) components, following a
protein conjugate analysis. The two peaks correspond to the RNA-protein
complex (peak 1; Mw 33.6 kDa) and the excess RNA (peak 2; Mw 11.0
kDa).
labelling of infected BHK-21 cells (11,23). The frameshift
efficiency of the SSmutant virus was low at both timepoints
(5% and 1%at 10 and 12 hpi respectively), as previously seen
for TMEV (23) and EMCV (24).
The 10 hpi timepoint was selected for the ribosome pro-
filing. BSR cells were infected with TMEV WT, SS or M3,
or mock-infected, and harvested by snap-freezing in liquid
nitrogen. Cells were lysed and the presence of 2A verified by
western blotting (Supplementary Figure S5A). Lysates were
treated with RNase I and ribosome-protected mRNA frag-
ments (RPFs) were harvested by pelleting the ribosomes
through sucrose with subsequent phenol extraction (Figure
6C). RPFs were ligated to adapters, cloned, and deep se-
quenced. Reads were mapped to the host (M. auratus) and
viral (based on NC 001366) genomes (Supplementary Ta-
ble S2) to determine precisely the locations of translating
ribosomes. Quality control analysis, carried out as previ-
ously described (62), indicated that the datasets were of high
quality (Supplementary Figure S5). RPFs mapping to cod-
ing sequences exhibited the characteristic length distribu-
tion with peaks at 20–22 nt and 28–30 nt (Supplementary
Figure S5B), corresponding to the two distinct lengths of
mRNA protected from nuclease digestion by the translat-
ing ribosome (60,63–66). In mammalian cell lysates treated
with sufficient nuclease so that all unprotected regions of
mRNA are fully digested (‘trimmed’), there is a distance
of ∼12 nt between the 5′ end of the RPF and the first nu-
cleotide in the P site of the ribosome (60). This can be used
to infer the frame of translation. In our libraries, the major-
ity of CDS-mappingRPF 5′ endsmap to the first nucleotide
position of codons (herein termed phase 0) (Supplementary
Figure S5C), indicating successful nuclease trimming. RPFs
map to coding sequences with a triplet periodicity reflective
of the length of a codon and, as expected, few RPFs map to
the UTRs (Supplementary Figure S5D).
2A-stimulated frameshifting occurs with 85% efficiency in in-
fected cells
To analyse translation of the viral RNA, we plotted RPF
distribution on the viral genome (Figure 6D–G, Supple-
mentary Figure S6). There is a clear dominance of the 0
phase throughout the genome (Figure 6E), including within
the + 1-frame L* ORF which overlaps L and VP0, indicat-
ing that the L* ORF is not highly translated. Ribosomes
that undergo frameshifting at the 2B* shift site translate
only eight codons in the −1 frame before encountering a
termination codon. This results in a striking drop-off in ri-
bosome density on the WT genome (Figure 6D). No such
decrease in density is seen after the frameshift site on the SS
virus genome, and there is actually a slight increase in read
density in this region on the M3 genome. This could be due
to differences between the two regions in mean translation
rate or the extent of various biasing effects inherent in the
ribosome profiling procedure, such as ligation, PCR or nu-
clease biases (67). In order to control for these effects and
highlight translational features related to the presence of a
functional 2A and/or shift site, the read densities on theWT
and SS genomes were divided by those in the correspond-
ing position on the M3 genome (Figure 6F, Supplementary
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Figure 6. 2A stimulates −1 PRF with 85% efficiency and leads to ribosomal pausing in infected cells. (A) Metabolic labelling of BSR cells infected with
WT, SS, or M3 TMEV and harvested at 10 hpi. Positions of TMEV proteins are indicated, with those downstream of the frameshift site written in red. (B)
Frameshift (FS) efficiency in infected cells, calculated from metabolic labelling (blue bars) and ribosome profiling (green bars). Bars represent the mean
of three replicates, with values for each replicate indicated by crosses. (C) Schematic of ribosome profiling methodology. Cells are flash frozen before lysis.
RNase I is added to digest regions of unprotected RNA, then ribosomes and enclosed ribosome-protected fragments (RPFs) of RNA are purified. RPFs
are released and prepared for high-throughput sequencing to determine the positions of translating ribosomes at the time of cell lysis. (D) RPF densities in
reads per million mapped reads (RPM) onWT, SS and M3 viral genomes (top panel), after application of a 15 nt running mean filter, from cells harvested
at 10 hpi. Positive sense reads are plotted in green (above the horizontal axis), negative sense in red (below the horizontal axis; negligible amounts). In all
plots, RPF densities from replicate 3 are shown, plotted at the inferred position of the ribosomal P site. (E) Positive-sense RPF densities from D, coloured
according to phase (purple, blue, and yellow represent RPFs whose 5′ ends map to, respectively, the first, second or third nucleotides of polyprotein-frame
codons, defined as phases 0, +1/−2 and + 2/−1), after application of a 15 codon running mean filter. Frames for each viral ORF are designated with
respect to the polyprotein (set to 0) and indicated on the genome map by colour and by an offset on the y axis in the corresponding direction. (F) Ratio of
WT or SS RPF density at each position on the genome relative to the RPF density on the M3 mutant genome. UTRs were excluded, only positive-sense
reads were used, and a 15 nt running mean filter was applied before the division. Regions defined as ‘upstream’ and ‘downstream’ in the ribosome profiling
frameshift efficiency calculations are annotated below, and average densities for these regions indicated to the left of the plots with grey lines. (G) Inferred
positions of ribosomal P sites at the slippery sequence and in the 2B* region, coloured according to the phase of RPF 5′ ends as in (E). The genome
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ratio of M3-normalised RPF density in the regions down-
stream and upstreamof the frameshift site, revealing amean
WT frameshift efficiency of 85%, which to our knowledge is
the highest − 1 PRF efficiency thus far recorded in any nat-
ural system (11,22,23) (Figure 6B, green bars). This is sig-
nificantly greater than the 63% measured by metabolic la-
belling at the same timepoint (two-tailed Welch’s t-test: t =
−10.2, df= 2.03, P= 0.0090). The profiling assay (withM3
normalisation) is expected to be substantiallymore accurate
than the metabolic labelling approach, which suffers from
lower sensitivity (densitometry of a few protein bands ver-
sus high throughput sequencing) and lower temporal reso-
lution (1 h labelling versus snap-freezing translating ribo-
somes).
The occurrence of a highly efficient frameshift in WT
TMEV was verified by the observation of a marked shift
in the dominant RPF phase from 0 in the upstream re-
gion, to −1/+2 in the 2B* transframe region (Figure 7A).
It should be noted that in frameshift efficiency calculations,
neither the profiling nor themetabolic labelling experiments
would reliably distinguish between ribosome drop-off due
to termination at the 2B* stop codon post-frameshifting
and ribosome drop-off at the StopGo site located just five
codons upstream. However, StopGo is generally very effi-
cient in cultured cells, with little drop-off (68,69), and this is
evident here, as no obvious decrease in RPF density occurs
after the StopGo motif in the M3 mutant (Figure 6D, Sup-
plementary Figure S6A). Surprisingly, the mean frameshift
efficiency of the SS mutant was high, at 15%. Similar resid-
ual frameshift activity has been observed at other highly
efficient frameshift signals with analogous mutations de-
signed to knock out frameshifting (70,71). This may be
reflective of the very strong frameshift-stimulatory activ-
ity of the 2A-RNA complex facilitating frameshifting even
despite unfavourable codon-anticodon repairing in the −1
frame. However, prolonged pausing of ribosomes over the
mutant slippery sequence (discussed below) could poten-
tially influence mechanisms other than frameshifting that
may contribute to this observed drop-off, such as ribosome
rescue pathways (72).
Profiling reveals multiple 2A-related ribosomal pausing
events
Ribosome pausing over the slippery sequence has long been
considered amechanistically important feature of PRF (16–
18,21). However, while observed to a small extent on WT
shift sites in vitro (23,70,73–75), it has been elusive in ri-
bosome profiling data (62,76). However, if the slippery se-
quence is mutated to prevent frameshifting, a measurable
pause is seen both in vitro (18,23,27) and in profiling ex-
periments (22), perhaps reflecting a reduced ability of non-
frameshifting ribosomes to resolve the topological prob-
lem posed by the downstream frameshift-stimulatory ele-
ment. Ribosome profiling can allow the identification of ri-
bosome pauses with single-nucleotide precision, but at the
level of individual nucleotides, the profiles can be strongly
affected by nuclease, ligation, and potentially other biases
introduced during library preparation. However, by com-
paring the WT and SS genome ribosome profiles with the
M3 genome ribosome profile, many of these biases are nor-
malised, allowing changes in dwell time to be identified that
are likely to arise as a result of 2A binding.
Apart from ribosome drop-off at the 2B* stop codon,
the region of greatest difference in a comparison of the
WT and M3 profiling datasets was surprisingly not at the
frameshift site, but in the middle of the 2A ORF (Fig-
ure 6F, Supplementary Figure S6B). This pause likely cor-
responds to ribosomes translating the RNA-binding argi-
nine residues (R85 and R87), which are mutated to ala-
nine in the M3 genome. The pause on the M3-normalised
plot likely reflects increased decoding time for the arginine-
encoding CGC codons in the WT, which are relatively
poorly adapted to the cellular tRNA pool compared to the
alanine-encoding GCC codons in the M3 mutant (57,77)
(Figure 7B and C). This peak is present to a lesser extent on
the SS genome, potentially due to the slightly slower repli-
cation kinetics of this mutant virus (11) meaning there are
fewer copies of the viral genome to deplete the cellular sup-
ply of the relevant amino-acylated tRNA.
Looking specifically at the frameshift site, a single-
nucleotide resolution plot of reads mapping to this region
reveals a peak on the SS mutant genome corresponding to
a ribosome paused with the GUG codon of the mutated
slippery sequence (corresponding to WT GUU) in the P
site (Figure 6G, Supplementary Figure S6C). This puta-
tive pause is present to a lesser extent on the WT genome
(marked 0 in purple), but not the M3 genome, indicating
it is related to the presence of functional 2A. The UUU
codon of the slippery sequence also appears to have a much
larger phase 0 peak in SS thanM3, however this may be en-
hanced by potential ‘run-on’ effects in which a fraction of ri-
bosome pauses may be able to resolve during cell harvesting
and ribosomes translocate to the next codon (77). On both
WT and SS genomes, a noticeable peak is present two nu-
cleotides downstream of the main slippery sequence pause,
corresponding to ribosomes which have frameshifted and
then translocated one codon, and further peaks suggestive
of − 1-frame translation throughout the 2B* ORF, espe-
cially on the WT template. Closer inspection of the whole-
genome (Figure 6D, Supplementary Figure S6A) and M3-
normalised plots (Figure 6F, Supplementary Figure S6B)
reveals that the pause at the frameshift site actually extends
a little further upstream, ending just upstream of the 2A-2B
junction formed by the StopGomotif. Further investigation
of this region (Figure 7B) reveals prominent pauses in the
SS mutant, and to a lesser extent the WT, with ribosomal
P sites corresponding to the glutamic acid and methionine
residues of the D(V/I)ExNPG|P StopGo motif (pause sites
highlighted in bold, where x ismethionine in TMEV). These
pauses are larger than the pause over the slippery sequence
itself. Ribosomal pausing over StopGo motifs has been ob-
served in vitro (69) but was shown to occur with the ribo-
somal P site corresponding to the conserved glycine residue
directly before the separation site (69,78), suggesting that
the pauses we see have another origin.
Disome profiling provides evidence for ribosome queuing at
the frameshift and StopGo sites
Noticing that the main pause over the StopGo motif
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Figure 7. Investigation of the region around the frameshift site by ribosome profiling. (A) Percentage of reads (all read lengths) attributed to each phase
in the regions upstream and downstream of 2B* and in the short 2B/2B* overlap region (‘transframe’). (B) Density of RPFs in the 200 nt up to and
including the frameshift site, plotted at inferred P site positions of the ribosomes, and coloured according to RPF phase as in Figure 6D. The encoded
amino acid sequence in this region is underlaid beneath the data in the top panel, and all libraries are set to the same scale on the y axis, with no running
mean filter applied. The last amino acid of 2A––after which StopGo-mediated peptide release occurs – is annotated in brown, the P site of frameshifting
(FS) in grey, and the RNA-binding arginines mutated to alanine in M3 in black. (C) Histogram of relative adaptiveness values of each sense codon to the
cellular tRNA pool, defined based on a combination of intracellular tRNA abundance and the strength of the codon-anticodon interaction. Values for the
Chinese hamster Cricetulus griseus were taken from the Species-Specific tRNA Adaptive Index Compendium (57) asM. auratus values were not available.
The adaptiveness values of the CGC arginine codons encoding R85 and R87, and the GCC alanine codons to which they are mutated in M3, are indicated
by dashed lines.
sequence, we wondered whether this might be consistent
with the transient formation of disomes, in which the lead-
ing ribosome is paused over the slippery sequence. Dis-
omes are routinely excluded during preparation of ribo-
some profiling libraries by the inclusion of a size-selection
step (in this study, 19–34 nt) which selects for monosome-
protected fragments (60). For mock, WT- and M3-infected
lysates from replicate 3 we carried out two parallel size se-
lection steps, in which the 19––34 nt ‘monosome’ fraction
and a 35–65 nt ‘broad spectrum’ fraction were isolated from
the same lysate. The length distribution of broad spectrum
reads demonstrated local peaks at read lengths of around
51, 54 and 59–63 nt, consistent with expected lengths of
RNA protected by disomes (64,79,80) (Figure 8A). Reads
of lengths 51–52, 54–55 and 57–64 nt showed a bias in phase
composition towards phase 0, indicating a portion of gen-
uine ribosome footprints (Figure 8B). These read lengths





















































































Nucleic Acids Research, 2021 17
Figure 8. Profiling of disome-protected fragments reveals ribosome stacking at the frameshift site. (A) Length distribution of reads mapping within host
CDSs for broad spectrum libraries. (B) Total number of reads attributed to each phase, for reads of each specified length, in the broad-spectrum libraries.
Read lengths which were selected for inclusion in the ‘disome-protected fragment’ plots (C and D) are indicated by square brackets, and correspond to
peaks in (A). (C) Density of disome-protected fragments on the WT and M3 viral genomes, derived from the same lysate as the monosome-protected
fragment data plotted in Figure 6D–G. Reads of lengths 51–52, 54–55 and 57–64 nt were selected for inclusion, and read densities are plotted as RPM after
application of a 15 nt running mean filter. Positive-sense reads are plotted in green (above the horizontal axis), negative sense in red (below the horizontal
axis). In all disome plots, reads are plotted at the inferred P site position of the colliding ribosome. (D) Density of disome-protected fragments, plotted at
inferred P site positions of colliding ribosomes involved in disomes upstream of the 2B* frameshift site, coloured according to phase as in (B). The encoded
amino acid sequence in this region is underlaid beneath the data in the top panel, and both libraries are set to the same scale on the y axis, with no running
mean filter applied. Codons on which leading ribosomes would be expected to pause due to StopGo and frameshifting (FS) are indicated in brown and
grey respectively. Positions of ribosomes potentially involved in queue formation behind these pause sites are indicated (FS: above genome map; StopGo:
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fragments’, and their density plotted on the viral genome
at the inferred P site position of the upstream, colliding ri-
bosome (Figure 8C and D).
A very prominent peak is visible on the WT genome over
the StopGomotif (Figure 8C), and closer inspection reveals
that one of the highest peaks in this region is over the valine
of the StopGo motif, ten codons upstream of the slippery
sequence pause (Figure 8D). This is the expected distance
between the P sites of ribosomes involved in a disome (79–
81), and would be consistent with disome formation due to
a ribosome translating the StopGomotif colliding with a ri-
bosome paused over the slippery sequence. Further, this ap-
proximate ten-codon periodicity in distances between peaks
extends upstream, consistent with potential formation of ri-
bosome queues up to six ribosomes long (80,82) (Figure 8D,
grey oblongs). An additional peak is evident over the argi-
nine codon ten codons upstream of the StopGo release site,
which would correspond to a disome in which the leading
ribosome was paused over the conserved glycine codon of
the StopGo motif (Figure 8D, brown oblongs). This is evi-
dently a feature of the StopGo site itself and unrelated to the
binding of 2A downstream, as it occurs in the M3 dataset
as well as the WT. It should be noted that ribosome profil-
ing generates an averaged result of ribosome positions over
multiple copies of the viral genome, and formation of the
two putative disomes proposed here could not occur simul-
taneously on a single RNA.
The potential formation of ribosome queues behind the
frameshift/StopGo site is supported by the monosome
data, in which RPF density gradually increases throughout
2A, reaching a maximum over the StopGo motif. This is
particularly apparent in the data from the SS mutant (Fig-
ure 6D and F), consistent with the idea that greater paus-
ing over the mutant slippery sequence may be increasing
disome formation, pushing the lengths of protected frag-
ments into the disome fraction, and reducing their visibil-
ity in the monosome dataset. This is unusual, as no promi-
nent disome peaks were detected near the frameshift site by
broad spectrum ribosome profiling of murine coronavirus
(62), nor at the −1 PRF site of L-A virus in yeast (83), al-
though we note that −1 PRF is less efficient in both these
systems when compared with TMEV. Indeed, the potential
formation of disomes at the frameshift site in TMEV repre-
sents the first evidence of ribosomes forming queues at a− 1
PRF signal in a eukaryotic system. Disome formation has
recently beenmechanistically implicated in +1 PRF in yeast
and +1 and −1 PRF in bacteria (83–86). It may be that the
impact of ribosomes colliding at the TMEV PRF site con-
tributes to the complex energetic and conformational land-
scape required to overcome the translation blockade and
break the triplet codon periodicity.
CONCLUSION
Our combination of structural, biophysical, biochemical
and deep sequencing approaches affords a view of un-
paralleled detail into the molecular mechanisms underpin-
ning Theilovirus protein-stimulated frameshifting. Despite
highly divergent sequences within cardioviruses, the TMEV
2A protein adopts the second known occurrence of the
beta-shell fold. Whilst the distribution of positively charged
residues comprising the putative RNA-binding surface is
different from that found in EMCV, it nevertheless reca-
pitulates the same exquisite conformational selectivity for
binding to its viral RNA target. Strikingly, we demonstrate
that this is a pseudoknot that is likely to exist in equilibrium
with the stem-loop previously suggested by structure prob-
ing experiments.Despite being 11 nt shorter, the stimulatory
RNA element is able to adopt a conformation topologically
equivalent to that previously seen in EMCV, involving inter-
actions between the loop and the 5′ extension. In infected
cells, stabilisation of this conformation by high-affinity 2A
binding represents the ‘switch’ that controls frameshifting
and thereby reprogramming of viral gene expression. Our
ribosome profiling data reveals that, when invoked, this is
up to 85% efficient, representing the highest known−1 PRF
efficiency to date. Whilst frameshift-associated pausing is
not normally detectable at WT shift sites in profiling data,
we show that it is detectable here by analysing RPFs corre-
sponding to disomes, not only at the PRF site but also the
adjacent StopGomotif. This is consistent with the relatively
long pauses accompanying TMEV frameshifting in vitro,
and suggests that ribosome collisions are more common
than previously thought during translation of the TMEV
genome. Taken together, these results suggest that there is
a fine balance between necessary ribosome pausing asso-
ciated with recoding events, and the detrimental effect on
viral fitness that may result from these pauses lasting long
enough to trigger ribosome quality control pathways, and
the degradation of the viral RNA. In future, structural char-
acterisation of the 2A-RNA complex will yield further in-
sights into the molecular mechanisms underlying the po-
tency of this elongation blockade.
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